Silk Road Medical (FRA:2OW) ROCE % : -21.35% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Silk Road Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Silk Road Medical's annualized ROCE % for the quarter that ended in Mar. 2024 was -21.35%.

Silk Road Medical ROCE % Historical Data

The historical data trend for Silk Road Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silk Road Medical ROCE % Chart

Silk Road Medical Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-62.55

-29.45

-33.91

-27.16

-20.05

Silk Road Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-24.28	-19.59	-18.72	-18.91	-21.35

Silk Road Medical ROCE % Calculation

Silk Road Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-44.816	/	( ( (254.583 - 23.117)	+	(243.288 - 27.77) )	/ 2 )
	=	-44.816	/	( (231.466	+	215.518)	/ 2 )
	=	-44.816	/	223.492
	=	-20.05 %

Silk Road Medical's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-45.688	/	( ( (243.288 - 27.77)	+	(232.129 - 19.63) )	/ 2 )
	=	-45.688	/	( ( 215.518	+	212.499 )	/ 2 )
	=	-45.688	/	214.0085
	=	-21.35 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Silk Road Medical (FRA:2OW) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Silk Road Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Silk Road Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Silk Road Medical (FRA:2OW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Silk Road Medical Inc (FRA:2OW) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SILK:USA

Address

1213 Innsbruck Drive, Sunnyvale, CA, USA, 94089

Website

https://www.silkroadmed.com

Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.

Silk Road Medical (FRA:2OW) Headlines

No Headlines